These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6208468)

  • 1. Evaluation of cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with cytosine arabinoside: a report from Children's Cancer Study Group.
    Movassaghi N; Higgins G; Pyesmany A; Baehner R; Chard R; Sather H; Hammond D
    Med Pediatr Oncol; 1984; 12(5):352-6. PubMed ID: 6208468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
    Presant CA; Berger NA; Klahr C; Phillips GL
    Cancer; 1980 Jul; 46(1):22-8. PubMed ID: 6930320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors.
    Finklestein JZ; Higgins G; Krivit W; Hammond D
    Cancer Treat Rep; 1979 Aug; 63(8):1331-3. PubMed ID: 89907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: a randomized collaborative study.
    Mandelli F; De Lipsis E; Grignani F; Martelli M; Liso V; Amadori S
    Med Pediatr Oncol; 1978; 4(3):231-40. PubMed ID: 277749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia.
    Whitlock JA; Wells RJ; Hord JD; Janco RL; Greer JP; Gay JC; Edwards JR; McCurley TL; Lukens JN
    Leukemia; 1997 Feb; 11(2):185-9. PubMed ID: 9009078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased survival in childhood acute nonlymphocytic leukemia after treatment with prednisone, cytosine arabinoside, 6-thioguanine, cyclophosphamide, and oncovin (PATCO) combination chemotherapy.
    Chard RL; Finklestein JZ; Sonley MJ; Nesbit M; McCreadie S; Weiner J; Sather H; Hammond GD
    Med Pediatr Oncol; 1978; 4(3):263-73. PubMed ID: 355821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.
    Woods WG; Ruymann FB; Lampkin BC; Buckley JD; Bernstein ID; Srivastava AK; Smithson WA; Benjamin DR; Feig SA; Kim TH
    Cancer; 1990 Sep; 66(6):1106-13. PubMed ID: 2205352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
    Kornblau SM; Kantarjian H; O'Brien S; Andreeff M; Koller CA; Beran M; Keating M; Estey E
    Leuk Lymphoma; 1998 Jan; 28(3-4):371-5. PubMed ID: 9517508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclocytidine in the treatment of refractory acute childhood leukemia: a Southwest Oncology Group Phase I-II study.
    Miale T; Hvizdala E; Ragab A; Pullen J; O'Brien P; McMillan C
    Cancer Treat Rep; 1979; 63(11-12):1913-5. PubMed ID: 93513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved prognosis of acute nonlymphocytic leukemia in children: results of the 12th-ANLL protocol of Tokyo Children's Cancer Study Group.
    Bessho F; Kigasawa H; Tsuchida M; Tsukimoto I; Nakazawa S; Yamamoto M; Tsunematsu Y; Yamada K; Sugita K; Ohkawa Y
    Acta Paediatr Jpn; 1991 Aug; 33(4):533-9. PubMed ID: 1792913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Am J Hematol; 1990 Sep; 35(1):22-5. PubMed ID: 2202204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group.
    Miller LP; Pyesmany AF; Wolff LJ; Rogers PC; Siegel SE; Wells RJ; Buckley JD; Hammond GD
    Cancer; 1991 May; 67(9):2235-40. PubMed ID: 1707336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
    Esumi N; Todo S; Arakawa S; Imashuku S
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diaziquone and 2,2'-anhydro-arabinosyl-5-fluorocytosine for the treatment of children with relapsed or refractory acute nonlymphoblastic leukemia.
    Meyers PA; Tan CT; Steinherz PG; Redner A
    Cancer; 1989 Dec; 64(12):2416-9. PubMed ID: 2479459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.